Palifermin for oral mucositis in the high-dose chemotherapy and stem cell transplant setting: The Royal Adelaide Hospital Cancer Centre experience

Supportive Care in Cancer

Volumn 14, Issue 6, 2006, Pages 580-582

  Keefe, Dorothy ^a   Lees, Jude ^a   Horvath, Noemi ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEAM PROTOCOL; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; KERATINOCYTE GROWTH FACTOR; MELPHALAN; PODOPHYLLOTOXIN;

ADULT; ARTICLE; AUSTRALIA; CANCER CENTER; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG ERUPTION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PRIMARY PREVENTION; STOMATITIS; TIME; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CANCER CARE FACILITIES; CARMUSTINE; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; FEMALE; FIBROBLAST GROWTH FACTOR 7; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; MALE; MELPHALAN; MIDDLE AGED; PODOPHYLLOTOXIN; PRIMARY PREVENTION; SEVERITY OF ILLNESS INDEX; SOUTH AUSTRALIA; STOMATITIS; TIME FACTORS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 33746094709     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-006-0048-3     Document Type: Article

References (6)

1. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, Shea T, Yanovich S, Hansen K, Noga S, McCarty J, LeMaistre CF, Sung EC, Blazar BR, Elhardt D, Chen MG, Emmanouilides C (2005) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351(25):2590-2598
2. Aaronson SA et al (1991) Keratinocyte growth factor: a fibroblast growth factor family member with unusual target cell specificity. Ann N Y Acad Sci 638:62-77
3. Sonis ST et al (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100(Suppl 9):1995-2025 (Pubitemid 38528741)
4. Clarke SJ, Abdi E, Davis D (2001) Recombinant human keratinocyte growth factor (rHuKGF) prevents chemotherapy-induced mucositis in patients with advanced colorectal cancer: a randomized phase II trial. Proceedings of ASCO 20:383a (abstract)
5. Farrell CL et al (1998) Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 58(5):933-939 (Pubitemid 28182461)
6. Farrell CL et al (1999) Effects of keratinocyte growth factor in the squamous epithelium of the upper aerodigestive tract of normal and irradiated mice. Int J Radiat Biol 75(5):609-620 (Pubitemid 29243139)